ABAna Benzaquén

Ana Benzaquén

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ana Benzaquén has a total of 190 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Treosulfan/fludarabine versus thiotepa/busulfan/fludarabine for allogeneic haematopoietic cell transplantation in lymphoma in the post‐transplant cyclophosphamide era: A GETH ‐ TC study

    by Marta Peña, Lorenzo Lazzari, Diego F. Martínez, Fabio Ciceri, Aitana Balaguer‐Roselló, Jaime Sanz, Maria J. Pascual, Ana Benzaquén, José L. Piñana, Maria Q. Salas, et al.

    Summary: Allogeneic haematopoietic cell transplantation (alloHCT) remains a potentially curative strategy for relapsed or refractory lymphoid malignancies, even in the post‐chimeric antigen receptor T‐cell and bispecific antibody era. While reduced‐intensity conditioning regimens offer lower non‐relapse mortality (NRM), relapse rates remain high, and optimal conditioning strategies in the setting of post‐transplant cyclophosphamide (PTCy) prophylaxis remain undefined. In this retrospective, international multicentre study, the primary end‐point was NRM. We compared treosulfan/fludarabine (Treo/Flu) versus thiotepa/busulfan/fludarabine (TBF) in 178 adults with lymphoid malignancies undergoing first alloHCT with PTCy and peripheral blood grafts. Three‐year NRM was 14.0% with Treo/Flu versus 33.0% with TBF. On multivariate analysis, Treo/Flu was associated with significantly lower 3‐year NRM (hazard ratio [HR] 0.44; 95% confidence interval [CI], 0.22–0.87; p = 0.018). Conditioning regimen was not independently associated with overall survival (OS) or progression‐free survival (PFS), and relapse incidence was similar between regimens. Moderate to severe chronic graft‐versus‐host disease (GVHD) was higher with Treo/Flu (26.0% vs. 9.9%; HR 2.43; 95% CI, 1.09–5.43; p = 0.03), while GVHD‐free/relapse‐free survival (GFRS) was comparable. Findings were consistent in a prespecified propensity score‐matched sensitivity analysis. These findings support Treo/Flu as a potentially safer reduced‐toxicity conditioning option than TBF in the context of PTCy‐based GVHD prophylaxis for lymphoid malignancies and warrant prospective validation.


  • EASIX Does Not Add Prognostic Value Beyond Lactate Dehydrogenase and ECOG Performance Status in CAR T-Cell Therapy: A GETH-TC Study

    by Marta Peña, Diego Fernando Martinez, Lucía López-Corral, Ana África Martín-López, Mario Sanchez-Salinas, Ana Benzaquén, Rafael Hernani, Jaime Sanz, Aitana Balaguer, Mar Perera, et al.

  • Thiotepa, busulfan and fludarabine conditioning regimen for adult patients with lymphoid malignancies undergoing allogeneic stem cell transplantation: a study on behalf of GETH-TC

    by M. Peña, D. F. Martinez, A. Paviglianiti, A. Balaguer, J. Sanz, M. J. Pascual, B. Herruzo, C. Solano, A. Benzaquén, M. Q. Salas, et al.

    The efficacy of thiotepa, busulfan, and fludarabine (TBF) conditioning in lymphoproliferative disorders remains under investigation. We analyzed outcomes in 157 patients with lymphoid malignancies who underwent a first allogeneic hematopoietic stem cell transplantation (alloHCT) following TBF conditioning. Non-relapse mortality (NRM) at 3 years reached 32%, while the cumulative incidence of relapse (CIR) was 19%. At 3 years, progression-free survival (PFS), overall survival (OS), and graft-versus-host disease (GVHD)-free/relapse-free survival (GRFS) were 49.7%, 58.0%, and 44.2%, respectively. The cumulative incidences of grade III-IV acute GVHD at 100 days and moderate-to-severe chronic GVHD at 3 years were 8.3% and 12%, respectively. On multivariate analysis, patients receiving high-dose thiotepa (10 mg/kg) demonstrated a significantly lower CIR than those receiving low-dose thiotepa (5 mg/kg) (HR 2.95 [95% CI, 1.37–6.33], p = 0.006), with no significant effect on NRM. Female donor-to-male recipient transplants were associated with reduced OS (HR 2.0 [95% CI, 1.17–3.44], p = 0.011) and increased NRM (HR 2.43 [95% CI, 1.29–4.35], p = 0.005). TBF conditioning demonstrated a substantial anti-tumor effect, counterbalanced by elevated toxicity. Careful patient selection and effective toxicity mitigation strategies are essential to ensure individuals can tolerate TBF’s toxicity while maximizing its benefits in disease control.


  • Ruxolitinib in acute and chronic graft-versus-host disease: real life long-term experience in a multi-center study for adult and pediatric patients, on behalf of the GETH-TC

    by Virginia Escamilla-Gómez, Valentín García Gutiérrez, Patricia Alcalde-Mellado, Beatriz Astibia-Mahillo, Anabelle Chinea-Rodriguez, Lucía López-Corral, Marina Acera-Gómez, Melissa Karina Torres Ochando, Asunción Borrero Borrego, Leslie González Pinedo, et al.

    Ruxolitinib has been approved for the treatment of adults and pediatric patients ≥12 years with steroid refractory graft-versus-host disease (GvHD). However, real-life studies are needed to confirm the results of clinical trials and further assess its efficacy in special populations. We performed a descriptive, retrospective, multi-center study of 352 adults and 42 pediatric patients treated with ruxolitinib for steroid-refractory acute or chronic GvHD. Among 119 and 233 adult patients with acute and chronic GvHD, overall response rate (ORR) was 58.8% (CR 33.6%) and 65.7% (CR 18.5%), respectively. Corticosteroids were withdrawn in 59.2% and 40.1%, and ruxolitinib in 47.2% and 34.8% in the acute and chronic groups of responders. Among 29 and 13 pediatric patients with acute and chronic GvHD, ORR was 82.7% (CR 51.7%) and 100% (CR 23%), respectively. Among responder patients, corticosteroids were withdrawn in 72.7% and 50%, and ruxolitinib in 75% and 30.7% in both groups respectively. Ruxolitinib in the real world setting, showed similar results as compared to clinical trials. Its efficacy is maintained in subsequent lines of treatment. In the pediatric population, the data are more favorable. In the long-term follow-up, corticosteroids, ruxolitinib and other inmunosuppressive drugs could be eliminated in a remarkably proportion of patients.


  • Open Access

    Ruxolitinib in Acute and Chronic Graft-Versus-Host Disease: Real Life Long-Term Experience in a Multi-Centre Study for Adult and Pediatric Patients, on Behalf of GETH-TC

    by José A Pérez-Simón, Virginia Escamilla-Gomez, Valentín García-Gutiérrez, Patricia Alcalde-Mellado, Beatriz Astibia Mahillo, Anabelle Chinea, Lucia Lopez-Corral, Marina Acera-Gómez, Melissa Torres Ochando, Asunción Borrero Borrego, et al.

    Ruxolitinib has been approved for the treatment of adults and pediatric patients ≥ 12 years with steroid refractory graft-versus-host disease (GvHD). However, real-life studies are needed to confirm the results of clinical trials and further assess its efficacy in special populations. We performed a descriptive, retrospective, multi-centre study of 352 adults and 42 pediatric patients treated with ruxolitinib for steroid-refractory acute or chronic GvHD. Among 119 and 233 adult patients with acute and chronic GvHD, overall response rate (ORR) was 58.8% (CR 33.6%) and 65.7% (CR 18.5%), respectively. Corticosteroids were withdrawn in 59.2% and 40.1%, and ruxolitinib in 47.2% and 34.8% in the acute and chronic groups of responders. Among 29 and 13 pediatric patients with acute and chronic GvHD, ORR was 82.7% (CR 51.7%) and 100% (CR 23%), respectively. Among responder patients, corticosteroids were withdrawn in 72.7% and 50%, and ruxolitinib in 75% and 30.7% in both groups respectively. Ruxolitinib in the real world setting, showed similar results as compared to clinical trials. Its efficacy is maintained in subsequent lines of treatment. In the pediatric population, the data are more favourable. In the long-term follow-up, corticosteroids, ruxolitinib and other inmunosuppressive drugs could be eliminated in a remarkably proportion of patients.

  • Open Access

    EEG before chimeric antigen receptor T-cell therapy and early after onset of immune effector cell-associated neurotoxicity syndrome

    by Rafael Hernani, Mika Aiko, Ruth Victorio, Ana Benzaquén, Ariadna Pérez, José Luis Piñana, Juan Carlos Hernández-Boluda, Paula Amat, Irene Pastor-Galán, María José Remigia, et al.


  • Top Cited Papers

    Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

    by Gloria Iacoboni, Víctor Navarro, Ana África Martín-López, Kai Rejeski, Mi Kwon, Katarzyna Aleksandra Jalowiec, Paula Amat, Juan Luis Reguera-Ortega, Laura Gallur, Viktoria Blumenberg, et al.

    PURPOSE: Approximately 30%-40% of patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) infused with CD19-targeted chimeric antigen receptor (CAR) T cells achieve durable responses. Consensus guidelines suggest avoiding bendamustine before apheresis, but specific data in this setting are lacking. We report distinct outcomes after CAR T-cell therapy according to previous bendamustine exposure. METHODS: The study included CAR T-cell recipients from seven European sites. Safety, efficacy, and CAR T-cell expansion kinetics were analyzed according to preapheresis bendamustine exposure. Additional studies on the impact of the washout period and bendamustine dose were performed. Inverse probability treatment weighting (IPTW) and propensity score matching (PSM) analyses were carried out for all efficacy comparisons between bendamustine-exposed and bendamustine-naïve patients. RESULTS: The study included 439 patients with R/R LBCL infused with CD19-targeted commercial CAR T cells, of whom 80 had received bendamustine before apheresis. Exposed patients had significantly lower CD3+ cells and platelets at apheresis. These patients had a lower overall response rate (ORR, 53% v 72%; P < .01), a shorter progression-free survival (PFS, 3.1 v 6.2 months; P = .04), and overall survival (OS, 10.3 v 23.5 months; P = .01) in comparison with the bendamustine-naïve group. Following adjustment methods for baseline variables, these differences were mitigated. Focusing on the impact of bendamustine washout before apheresis, those with recent (<9 months) exposure (N = 42) displayed a lower ORR (40% v 72%; P < .01), shorter PFS (1.3 v 6.2 months; P < .01), and OS (4.6 v 23.5 months; P < .01) in comparison with bendamustine-naïve patients. These differences remained significant after IPTW and PSM analysis. Conversely, the cumulative dose of bendamustine before apheresis did not affect CAR-T efficacy outcomes. CONCLUSION: Recent bendamustine exposure before apheresis was associated with negative treatment outcomes after CD19-targeted CAR T-cell therapy and should be therefore avoided in CAR T-cell candidates.


  • Open Access

    CART-AI-Radiomics: Survival and Neurotoxicity Prediction in B-Cell Lymphoma Patients Treated with CAR-T Cells through an Imaging Features-Based Model

    by Blanca Ferrer Lores, Alicia Serrano, Rafael Hernani, Pablo Sopena-Novales, Laura Ventura Lopez, Ana Isabel Teruel, Alfonso Ortiz Algarra, Ana Saus Carreres, Ignacio Arroyo Martin, Alexandru Robert Vasile Tudorache, et al.

    Disclosures. Hernandez Boluda:Pfizer, BMS, Incyte, and Novartis: Membership on an entity's Board of Directors or advisory committees. Guerreiro:Novartis, Kite,


  • Open Access

    Digital Polymerase Chain Reaction (dPCR) Versus Flow Cytometry (FC), a Validation Study for CAR-T Cell Product Optimal Detection

    by Laura Ventura, Alicia Serrano, Blanca Ferrer Lores, Paula Amat Martinez, Maria Jose Remigia Pellicer, Irene Pastor Galan, Paula Coll Ferri, Julia Ara Navarro, Paula Espinosa Molina, Elena Montolio Baselga, et al.

    CONCLUSIONS: Adoptive immunotherapy with Chimeric Antigen Receptor - T cells (CAR-T), has revolutionized hematological treatment mainly in relapsed/refractory (r/r) B-cell malignancies. CAR-T cells constitute challenging living drugs with heterogeneous in vivo cellular kinetics and adverse side effects that emphasizes the importance of its accurate detection and monitoring. Diagnostic assays are required for precise CAR-T quantification. Digital PCR (dPCR) is characterized by a high specificity, sensitivity and reproducibility, therefore we developed a study to implement this technique for CAR-T detection and compare its efficacy against Flow Cytometry (FC). Duplex dPCR assays were performed to concomitantly amplify CAR and RPP30 (reference gene) sequences using ddPCR Expert Design Assay: CD-19 CAR-T Assay (Bio-Rad, California, USA) with QIAcuity Digital PCR System and data analysis with QIAcuitySoftware Suite (QIAGEN, Germany). To assess sensitivity, a Axicabtagene Ciloleucel (Axi-Cel ®) original product obtained from leftovers's infusion bag patient was employed to perform dPCRs on serial dilutions using genomic DNA(gDNA) from a wild type (WT) patient. Specificity was ensured using WT and no template controls (NTC). Two independent dPCR assays with replicates for each sample were conducted to assess reproducibility. For FC comparative study, CAR-T cells percentage (%CAR-T) was determined by both techniques at variable post-infusion intervals (n=210) in different sample types, peripheral blood (n=205) and cerebrospinal fluid (n=5). Anti-FMC63 scFv Antibody, Mouse IgG1 (Acro biosystems) was employed, using FACSCanto II®, Becton-Dickinson Biosciences with FACSDiva software ® (V8.0; BD) and InfinicytTM software (Cytognos SL, Salamanca, Spain), for data analysis. Correlation coefficients were determined using two-tailed Pearson statistics with a confidence interval of 95%. Statistical analyses were made with SPSS Software (IBM, Germany). The dPCR data collected of 2 independent dPCR assays revealed a good split between the negative and positive partitions for the targets evaluated, showing a progressive decrease of the %CAR-T detected (63,88% - 4,12% - 0,77% - 0,08% - 0,01% - 0,00%). This reduction is correlated with the dilution factor applied to the series with an initial concentration of 50ng/µL both for CAR-T original product and WT gDNA. WT and NTC samples were negative with a SD=0; %CV=0, intra and inter-assays, evidencing thus the specificity of the technique. Positivity of the last (1 pg/µL) samples revealed a maximum sensitivity of 0.009 %CAR-T, threshold below which false positive results would be considered. WT gDNA did not influence the assay's sensitivity. 3 replicates of each sample and 2 independent dPCR assay were performed to study potential variations, exhibiting an excellent intra and inter-assay reproducibility with a minimal SD across dilutions ( Table.1.) Comparative study with FC revealed a light correlation between techniques with a Pearsons's correlation coefficient (R=0,553) ( p<0,001). Differences among both were enhanced for Minimal Residual Disease (MRD) evaluation from 60 days post-infusion monitoring (R=0,58) ( p=0,066) in which CAR-T cells can be detected applying dPCR up to 2 years and 9 months post-infusion, whereas being undetectable by FC. Complex CAR-T in vivo kinetics enhances the need for optimal diagnostic and monitoring techniques. dPCR is an ideal tool for precise CAR-T therapy evaluation with a higher grade of specificity, sensitivity and reproducibility than FC, mainly for MRD assessment. dPCR implementation and the establishment of standardized protocols across centers is required to improve CAR-T biology knowledge with a direct benefit on patient care.

  • Torque Teno Virus plasma DNA load: a novel prognostic biomarker in CAR-T therapy

    by Ana Benzaquén, Estela Giménez, Gloria Iacoboni, Manuel Guerreiro, Rafael Hernani, Eliseo Albert, Cecilia Carpio, Aitana Balaguer, Ariadna Pérez, Carlos S de la Asunción, et al.

    Torque Teno Virus (TTV) is a single-stranded circular DNA virus which has been identified as a surrogate marker of immune competence in transplantation. In this study we investigated the dynamics of plasma TTV DNAemia in 79 adult patients undergoing chimeric antigen receptor T-cell (CAR-T) therapy for relapsed or refractory large B-cell lymphoma, also evaluating the impact of TTV on immunotoxicities, response and survival outcomes. After lymphodepleting therapy, TTV DNA load was found to decrease slightly until reaching nadir around day 10, after which it increased steadily until reaching maximum load around day 90. TTV DNA load < 4.05 log10 copies/ml at immune effector cell-associated neurotoxicity syndrome (ICANS) onset identified patients at risk of progressing to severe forms of ICANS (OR 16.68, P = 0.048). Finally, patients who experienced falling or stable TTV DNA load between lymphodepletion and CAR-T infusion had better progression-free survival than those with ascending TTV DNA load (HR 0.31, P = 0.006). These findings suggest that TTV monitoring could serve as a surrogate marker of immune competence, enabling predictions of CAR-T efficacy and toxicity. This could pave the way for the development of TTV-guided therapeutic strategies that modulate clinical patient management based on plasma TTV load, similar to suggested strategies in solid organ transplant recipients.